Precision Optics Corporation, Inc. — Cyborg Score 4/10
Mixed
Optoelectronics
Strategic Profile
The company operates through medical devices and advanced defense/aerospace product segments. The company faces headwinds, with earnings declining 57.3% per year over the past 5 years, though it generated interest from fundamental institutional investors in its recent capital raise.
Cyborg Score Rationale
Precision Optics operates in attractive niche markets (medical optics, aerospace defense) with specialized capabilities, but faces significant operational challenges including multi-year earnings declines and limited analyst coverage. The recent capital raise signals management's effort to stabilize the business, yet profitability and growth momentum remain unclear.
Top Insights
Recent $10M capital raise (March 2026) suggests capital needs to fund operations or R&D in micro-optics and 3D imaging
Serves mission-critical medical and defense/aerospace segments with high barriers to entry, but customer concentration risk remains undisclosed
No analyst coverage (0 analysts) makes valuation opaque and reduces institutional visibility
Historical compliance issues with NASDAQ listing requirements (2004–2005) underscore past financial distress, though current listing status appears intact
Named Competitors
Optical components and systems — Optical components and imaging systems supplier
Medical imaging optics — Medical device manufacturer with optical imaging products
Aerospace/Defense optical systems — Aerospace & defense contractor with advanced optics capabilities
Recent Developments
(March 2026) Announced upsized $10 million public offering of 2,777,777 shares at $3.60 per share
(March 2026) Offered institutional participation from existing and new fundamental investors plus management involvement